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Abstract
Background: Standard treatment of hypophosphatemic rickets (HR) is oral phosphate tablets plus vitamin D. Due to the rapid
absorption of phosphate tablets, frequent daily doses are necessary, which is cumbersome and may cause fluctuations in plasma
phosphate and risk of secondary hyperparathyroidism. It was hypothesized that phosphate from milk or cheese is less rapidly ab-
sorbed, and reduces fluctuations in plasma phosphate.
Objectives: The current randomized, multiple crossover study aimed at investigating if an equivalent phosphate dose given as milk
or cheese is comparable to phosphate tablets in patients with HR.
Methods: Seven females with HR were included. They went through three different four-day treatment sessions of either oral phos-
phate tablets consisting of 800 mg elemental phosphorus divided into five doses over the day or an equivalent phosphorus dose
ingested as skimmed milk or cheese divided over five daily doses. Blood and urine samples were taken from patients after each
treatment session. Except the usual doses of vitamin D, no phosphate or calcium-modifying treatments were allowed. Statistical
analyses were performed using mixed models.
Results: Treatment feasibility was independent of the phosphorus source. The study demonstrated reduced plasma levels of
parathyroid hormone (PTH), reduced fluctuations in plasma phosphate and plasma PTH, and reduced renal phosphate excretion
when ingesting phosphorus supplementation as milk compared to phosphate tablets. The same trend was observed when admin-
istering phosphorus as cheese, though not statistically significant.
Conclusions: Phosphorus supplements can be administered as phosphate tablets, milk or cheese when given in equimolar doses.
The current study findings indicated that milk may be superior to phosphate tablets as the phosphate source in patients with HR.
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1. Background
Hypophosphatemic rickets (HR) are rare diseases with
an estimated incidence of 3.9 per 100,000 live births (1).
In approximately 80% of all familial HR cases, the disease
arises due to X-linked dominant inherited mutations in the
PHEX gene located at Xp22.2-p22.1 causing an increase in fi-
broblast growth factor 23 (FGF23) levels (2). FGF23 regulates
the phosphate homeostasis (3), and in HR, the increased
FGF23 leads to an excessive renal loss of phosphate (4),
which may result in rickets and/or osteomalacia, growth
failure, and dental complications (5). Furthermore, in-
creased FGF23 inhibits the enzyme 1α-hydroxylase, lead-
ing to an inappropriately low 1, 25-dihydroxyvitamin D
(1,25(OH)2D) concentration (6). Less commonly, familial
HR may be caused by an X-linked recessive inheritance
(CLCN5) or an autosomal dominant or recessive inheri-
tance (FGF23, DMP1, or ENPP1 mutation) (2, 7, 8). Alterna-
tively, but extremely rarely, excess FGF23 is produced by tu-
mors as in tumor-induced osteomalacia (TIO) (9).
HR is conventionally treated by a combination of oral
phosphorus supplementation and vitamin D and/or vi-
tamin D analogs. Careful titration is needed in order
to treat rickets/osteomalacia, and avoid side effects (5).
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To maintain an appropriate level of plasma phosphate
(P-phosphate), oral phosphate tablets should be admin-
istered four to five times daily, since the phosphate in
tablets is rapidly absorbed and excreted (10). P-phosphate
fluctuations with high peak concentrations may result
in increased secretion of parathyroid hormone (PTH) re-
sulting in secondary or eventually tertiary hyperparathy-
roidism, which further aggravates the phosphate excre-
tion and bone resorption causing bone demineralization
(11, 12); furthermore, nephrocalcinosis can occur as a con-
sequence (13). Secondary hyperparathyroidism may neces-
sitate treatment with cinacalcet to avoid constant high lev-
els of PTH (14) leading to tertiary hyperparathyroidism.
The literature is sparse concerning the effect of differ-
ent phosphorus sources on phosphate-calcium metabolic
parameters in patients with HR. It is observed that an
enhanced phosphorus content in food can disturb bone
metabolism (15). A study by Karp et al. (16) on healthy
females, evaluated the effect of equivalent phosphorus
amounts given as meat, cheese, whole grain, or phos-
phate supplementation as a mixture on calcium and bone
metabolism. They found the highest PTH concentrations
during treatment with phosphate mixture. Furthermore,
the urine phosphate (U-phosphate) was higher during the
phosphate mixture treatment compared with those of the
cheese and whole grain treatments. The results suggested
that the phosphorus source might influence phosphate-
calcium metabolism parameters.
To the best of authors’ knowledge, no studies evalu-
ated the effect of different phosphorus sources on phos-
phate and calcium metabolism to treat HR.
2. Objectives
On the grounds of the results found by Karp et al. (16),
the current study aimed at investigating the feasibility (pa-
tient compliance and satisfaction with treatment) and effi-
cacy of treatment with equivalent phosphorus doses given
as skimmed milk or cheese compared to phosphate tablets
in patients with HR evaluated by P-phosphate, P-PTH, and
U-phosphate excretion as the main effect parameters.
3. Methods
3.1. Participants and Protocol
Patients were selected from the outpatient clinics at
Aarhus University Hospital (Denmark) from August 2015 to
June 2016. All patients had genetically verified HR (Table
1) and were treated with oral phosphate tablets plus vita-
min D (cholecalciferol and/or alfacalcidol). Patients were
excluded from the study if they presented with tertiary hy-
perparathyroidism, were treated with cinacalcet, or had
milk allergy or lactose intolerance.
The current randomized (using: randomization.com),
multiple crossover study had three treatment sessions con-
sisting of ingestion of phosphate tablets, milk, or cheese
with equivalent phosphorus content. Each treatment ses-
sion lasted four days, and blood and urine samples were
taken on the 4th day. The patients were instructed to
discontinue their regular phosphate treatment and start
the phosphorus substitution (phosphate tablets, milk, or
cheese) three days prior to sample collection. Treatment
with active vitamin D was continued throughout the study
period and on the day of sampling. The patients were in-
structed to follow their normal dietary habits (amount and
source of diet) while participating in the study; the normal
diet was followed on the day of sampling as well. Patients
fasted overnight before specimen collection. There was at
least a four-day washout period between each treatment
session.
When phosphate supplementation was gives in the
form of tablets, the patients were treated with 800 mg of
elemental phosphorus divided into five doses over the day,
independent of any prior treatment dose. In the milk treat-
ment session, all patients received 800 mL of skimmed
milk divided into five meals corresponding to 800 mg of el-
emental phosphorus per day. In the cheese treatment ses-
sion, all patients received the same kind of cheese with es-
timated elemental phosphorus content of 800 mg divided
into five meals (18 g cheese per meal).
3.2. Sampling
On the 4th day of each treatment, the patients visited
the clinic for the collection of blood samples taken at five
time points during the day, including a fasting blood sam-
ple collected before any food or treatment at 8:00 a.m.
Blood samples were collected at 8:00 a.m. (fasting), 10:00
a.m., 12:00 a.m., 2:00 p.m., and 4:00 p.m. All blood sam-
ples were analyzed for total P-calcium, P-phosphate, P-PTH,
and P-FGF23; in addition, the fasting blood samples were
analyzed for serum 25-hydroxyvitamin D (25OHD), serum
1,25(OH)2D, and P-creatinine. On the day of blood sam-
pling, urine samples were also taken from the participants
twice: 1) between 8:00 a.m. and 12:00 a.m., and 2) between
12:00 a.m. and 4:00 p.m. According to standard operat-
ing procedures, blood samples for batch analysis were cen-
trifuged at 4000 rpm (3000 xg) for 10 minutes before be-
ing stored at -80°C until analysis. The urine samples were
stored at -20°C until analysis. U-phosphate excretion was
calculated as the U-phosphate concentration multiplied by
the urine volume.
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Table 1. Patients Characteristics and Biochemical Parameters Found in Fasting Blood Samples Taken at the Day After Treatments
Patient 1 2 3 4 5 6 7
Gender Female Female Female Female Female Female Female
Age, y 30 33 38 13 15 32 35
Weight, kg 88.4 76.2 80.6 38.0 52.2 70.2 93.2
Height, cm 159 157 159 132 137 156 180
Inheritance X-linked dominant X-linked dominant X-linked dominant X-linked dominant X-linked dominant X-linked dominant Autosomal dominant
Genetic variant PHEX, c1103G>A PHEX, c2239C>T PHEX, c1587-1G>C PHEX, c1587-1G>C PHEX, c1587-1G>C PHEX, pathogenic mutation FGF23, c536G>A
P-creatinine at 1st visit, umol/L 67 64 61 35 44 56 73
25OHD, nmol/L
Tablet 62 47 43 41 33 42 45
Milk 59 53 50 43 41 35 43
Cheese 56 74 38 43 38 31 -
1.25(OH)2 D (pmol/L)
Tablet < 25 47 < 25 53 < 25 75 57
Milk < 25 38 < 25 38 29 66 59
Cheese < 25 77 < 25 48 < 25 38 -
Except for the P-FGF23 analysis, all analyses were per-
formed according to standard laboratory techniques at
the Department of Clinical Biochemistry, Aarhus Univer-
sity Hospital. The 25OHD (reference range: 50 - 160 nmol/L)
and 1,25(OH)2D (reference range: 60 - 180 pmol/L) were ana-
lyzed by liquid chromatography-tandem mass spectrome-
try, both with total assay coefficient of variation (CV) of 10%.
PTH was analyzed using an immunometric assay (Cobas
6000, Roche Diagnostics Ltd., the UK) with total CV of 10%.
3.3. FGF23
C-terminal P-FGF23 concentrations were determined
using a two-site enzyme-linked immunosorbent assay
(ELISA), 2nd generation, from Immutopics Inc. (Human
FGF-23 (C-Term) ELISA Kit; Cat. # 60-6100 96), follow-
ing manufacturer’s instructions. Briefly, 100 µL of cali-
brators, controls, and EDTA (ethylenediaminetetraacetic
acid) plasma samples were pipetted onto the streptavidin-
coated plate. A 1:1 mixture of biotin- and HRP-labelled goat
polyclonal antibodies directed against the c-terminal re-
gion of P-FGF23 was added to the samples and the plate
was incubated for three hours at room temperature with
gentle shaking (200 rpm). The plate was then washed five
times with 350 µL of wash buffer and tetramethylbenzi-
dine was added to the plates (150 µL) followed by incuba-
tion for another 30 minutes in the dark with gentle shak-
ing (200 rpm). Absorbance was read at 620 nm before the
development was stopped with 50 µL of stop solution. Ab-
sorbance was read again at 450 nm (reference at 620 nm).
Absorbance at 620 nm was used for concentrations rang-
ing 451-1400 RU/mL, while absorbance at 450 nm for con-
centrations below 451 RU/mL. The normal range in adults
is < 100 RU/mL (17), intra-assay CV is 2.4%, and inter-assay
CV is 4.7%. FGF23 concentrations were analyzed at Bioana-
lytical Facility, University of East Anglia, Norwich, the UK.
3.4. Statistical Analysis
The outcome variables including P-phosphate, P-PTH,
total P-calcium, P-FGF23, and U-phosphate excretion were
analyzed in a mixed model with nested random effects to
account for the repeated observations on each subject and
within-subject levels in the crossover design. The fixed
part of the model included the treatment group and time
interaction and was further adjusted for treatment num-
ber and treatment order (the row and column effect of
the crossover design). Model validation was performed by
graphical inspection of residuals, fitted values, and ran-
dom effect estimates (BLUPs). P-FGF23 was analyzed using a
log scale. Residual variation, i e, the variation between ob-
servations in the same subject and within the same treat-
ment session, was group-specific and a test for difference
in variation was performed by comparing this model to the
model with equal variations by a likelihood ratio test. The
hypothesis of parallel mean curves over time between the
treatment groups was tested on the treatment-time inter-
action. Additionally, the overall group comparisons, com-
puted as the hypothesis of parallel mean curves, did not
seem implausible for any of the parameters. P-FGF23 was
back transformed and comparisons were relative. All anal-
yses were performed using Stata version 15 (IC) (StataCorp
LLC, 2017. College Station, TX). P values < 0.05 were consid-
ered statistically significant.
3.5. Ethical Considerations
The Danish Ethics Committee and the Danish Data Pro-
tection Agency approved the study protocol; the study was
also registered at ClinicalTrials.gov (NCT03348644). The
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patients were informed orally and in writing about the
project and both oral and written consents were obtained
before inclusion in accordance with the Declaration of
Helsinki. Approval to enroll patients under the age of 15
years was obtained from legal guardians.
4. Results
Seven females, aged 13 - 39 years, were included. Six of
the patients had dominant X-linked HR due to PHEX gene
mutations, while one patient had dominant autosomal HR
due to a mutation in the FGF23 gene. The characteristics
of the participants are presented in Table 1. In the cheese
treatment session, the patient with the autosomal dom-
inant mutation did not participate and another patient
did not give the blood sample at 4:00 p.m. In the phos-
phate tablets treatment session, one patient did not give
the blood sample at 4:00 p.m. During the other sessions,
all seven patients participated. The patients’ compliance
was not registered, but all patients reported 100% com-
pliance with the treatments. P-creatinine levels did not
change during the treatment period. Three patients had
low 1,25(OD)2D levels (Table 1).
Treatment feasibility was independent of the phospho-
rus source. One patient felt that the amount of cheese to be
ingested was ample, but she was assured and compliance
was 100%. None of the patients reported difficulties with
drinking extra 800 mL of milk daily.
Mean P-PTH was significantly lower during the treat-
ment with milk compared to phosphate tablets (P < 0.05)
(Table 2). However, P-phosphate, P-FGF23, and total P-
calcium levels did not differ significantly among the treat-
ments. Figure 1 presents the P-phosphate and P-PTH levels
by the time of day in the three treatment modalities. U-
phosphate excretion between 8:00 a.m and 4:00 p.m. was
significantly lower during the milk treatment session than
that of the phosphate tablets (P < 0.05) (Table 2).
A significant variation was observed in P-phosphate
and P-PTH fluctuations when comparing the three treat-
ment modalities (P < 0.01) and a significantly lower varia-
tion was observed when administering phosphate as milk
compared to phosphate tablets (P < 0.05) (Table 3 and Fig-
ure 2). The same trend was observed in the cheese treat-
ment session, although not statistically significant. There
was no significant difference in P-FGF23, total P-calcium, or
U-phosphate excretion when evaluating the fluctuations.
5. Discussion
The current study demonstrated reduced P-PTH and
reduced renal phosphate excretion and furthermore, re-
duced fluctuations in P-phosphate and P-PTH when admin-
istrating phosphate substitution to patients with HR as
milk compared to tablets. To the best of authors’ knowl-
edge, it was the first study reporting the effect of different
phosphorus sources when treating HR.
There is a known biological interaction between P-
phosphate and P-PTH. The increase of P-PTH leads to in-
creased phosphate excretion when P-phosphate is high.
Decreased P-PTH leads to reduced phosphate excretion
when P-phosphate is low (18). P-phosphate fluctuations
with high peak concentrations, possibly in combination
with reduced calcium concentrations, may be observed in
response to treatment with phosphate tablets leading to
increased P-PTH concentrations (12). The observation of
lower P-phosphate fluctuations when administering the
phosphorus source as milk combined with the reduced P-
PHT and reduced renal phosphate excretion is thought to
decrease the long-term risk of development of secondary
and tertiary hyperparathyroidism (12). Greater urine phos-
phate excretion during the period on tablets could indi-
cate that more phosphorus is absorbed from tablets than
from milk or cheese, or it may be due to the lower P-PTH
during the milk treatment session. However, P-phosphate
did not differ significantly among the treatment periods,
suggesting that the lower P-PTH during the milk session
caused the lower phosphate excretion. There was no sig-
nificant difference in P-FGF23 levels or fluctuations in P-
FGF23. It was, however, expected since X-linked dominant,
inherited mutations, as well as autosomal dominant inher-
itance cause increased levels of P-FGF23 independent of the
P-phosphate concentration (18). Three patients had very
low levels of 1,25(OH)2D (Table 1), and the other four pa-
tients had 1,25(OH)2D in the lower normal range. This may
also be expected since P-FGF23 decreases the expression of
the 1α-hydroxylase, thereby, inhibiting the hydroxylation
of 25OHD to 1,25(OH)2D (2).
Karp et al. (16) investigated the acute effect of dif-
ferent phosphorus sources (meat, cheese, whole grains,
and phosphate supplement as phosphate mixture) on cal-
cium and bone metabolism in 16 healthy females aged
20 - 30 years. They found that cheese increased the P-
phosphate concentration more than the other phospho-
rus sources when given in equimolar phosphorus quan-
tities. P-phosphate concentration remained significantly
higher the following morning. Phosphate mixture in-
creased U-phosphate excretion more than whole grain or
cheese. It was in line with the current study findings,
though not significant. Karp et al. (16) found that the S-
PTH concentrations differed among the different study ses-
sions. Cheese was associated with the greatest decrease in
S-PTH compared to all other phosphate sources. In con-
trast, phosphate mixture increased S-PTH concentrations
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Table 2. Mean Differences of P-phosphate, P-PTH, P-FGF23, Total P-calcium, and U-phosphate Excretion in Treatment Sessionsa
Milk vs. Tablet, Estimate (95% CI) Cheese vs. Tablet, Estimate (95% CI)
P-phosphate, mM/L -0.04 (-0.13; 0.04) -0.07 (-0.17; 0.02)
P-PTH, pmol/L -2.71b (-4.56; -0.86) 0.01 (-2.03; 2.05)
P-FGF-23c , RU/mL 1.00 (0.73; 1.36) 0.80 (0.58; 1.12)
Total P-calcium, mM/L 0.03 (-0.03; 0.09) -0.04 (-0.11; 0.02)
U-phosphate excretion, mM/L -1.79b (-3.23; -0.35) -1.39 (-2.94; 0.17)
aP-PTH and U-phosphate excretion was significantly lower during the treatment with milk compared to phosphate tablets.
bP values < 0.05.
cAnalyses were performed based on log-scale. Comparisons are relative.
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Figure 1. P-phosphate (A) and P-PTH (B) levels by time of day in the three treatment sessions after completing three-day treatment on the fourth day of treatment; a lower level
of P-PTH was observed during treatment with milk compared to phosphate tablets; P < 0.05.
Table 3. Variation in Effect Parameters in the Three Treatment Sessionsa
Tablet Milk Cheese P Value
P-phosphate, mM/L 0.08 (0.06; 0.1) 0.04 (0.03; 0.05) 0.07 (0.05; 0.09) < 0.01
P-PTH, pmol/L 2.51 (1.89; 3.34) 0.92 (0.69; 1.22) 1.56 (1.13; 2.14) < 0.01
P-FGF-23b , RU/mL 0.08 (0.06; 0.11) 0.11 (0.08; 0.15) 0.10 (0.07; 0.13) 0.32
Total P-calcium, mM/L 0.04 (0.03; 0.06) 0.04 (0.03; 0.05) 0.03 (0.02; 0.04) 0.21
U-phosphate excretion, mM 2.09 (1.36; 3.2) 0.92 (0.46; 1.85) 1.29 (0.75; 2.22) 0.06
aP values compared the variation in the three groups.
bAnalyses were performed based on log-scale.
compared to the control session. Meat or whole grain had
no effect on S-PTH (16). Also, an insignificant trend of re-
duced P-PTH fluctuation and reduced U-phosphate excre-
tion was observed when ingesting phosphorus as cheese.
It was speculated that the reduction in P-PTH fluctuations
when ingesting phosphorus as milk or cheese was caused
by prolonged phosphorus absorption. However, the exact
mechanism remains to be elucidated.
In the future, human anti-FGF23 antibody may become
an alternative treatment for HR caused by elevated P-FGF23
(19, 20). However, phosphorus supplements are still ex-
pected to be a necessary treatment option in HR as human
anti-FGF23 antibodies might not be available in all coun-
tries, and their efficacy over time needs further verifica-
tion. Furthermore, milk as phosphorus source may be an
alternative to phosphate tablets in other phosphate wast-
ing diseases such as renal tubular acidosis or TIO (21).
Although the low number of the studied patients was a
limitation of the study, it was a strength point that signifi-
cant differences were demonstrated on the effect of param-
eters in the three treatment arms. Hereditary HR is a rare
disease leaving difficulties in recruiting a larger study pop-
ulation. Furthermore, several patients in the current study
received cinacalcet treatment, and were thereby excluded.
Other limitations were the duration of the study, which
only provided short-term information on the biochem-
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Figure 2. Variations around the mean levels of P-phosphate (A) and P-PTH (B) (residuals vs. fitted) in the three treatment sessions; P-phosphate and P-PTH fluctuations were
significantly lower when the patients received phosphate via milk compared to tablets.
istry, and the fact that there was no information regarding
the phosphate content in the patients’ regular diet dur-
ing treatment interventions. However, the patients were
instructed to follow their usual dietary habits regarding
both the amount and source of food.
Participants were only females, but no difference is
expected in the pathophysiological mechanism of phos-
phate processing between males and females.
5.2. Conclusions
The current pilot study showed that the phosphorus
supplement in patients with HR when given in equimo-
lar phosphorus doses could be administered as phosphate
tablets, milk, or cheese with similar phosphorus concen-
trations independent of the source. However, mean P-PTH
level and U-phosphate excretion were significantly lower
during treatment with milk compared to treatment with
phosphate tablets. Furthermore, reduction of P-phosphate
and P-PTH fluctuations after ingesting phosphorus as milk
was statistically significant, suggesting that milk is less
likely to be associated with unwarranted effects on the
calcium-phosphate homeostasis compared to phosphate
tablets in patients with HR. Since the study population was
small and the differences in the effect parameters among
treatments were also small, though statistically signifi-
cant, the current study results need to be confirmed in a
larger population.
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